Winnergy Medical Public Company Limited (WINMED) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Winnergy Medical Public Company Limited stock THB 0.56, price THB 1.18, that is 52.5% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 0.7400 THB – 7.46 THB · fair‑value band 0.2600 THB – 0.7100 THB · the 1.18 THB price screens above the 0.5600 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Winnergy Medical Public Company in your weekly email
Every Wednesday you see whether Winnergy Medical Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Winnergy Medical Public Company Limited engages in the distribution of medical and diagnostic equipment in Thailand.
Show moreShow less
The company imports and distributes technology and diagnostic kits for cervical cancer screening, including cytology examinations using automatic slide preparation machines and testing for human papilloma virus, and colposcopes.
It also offers equipment for testing blood quality and blood collection bags for blood donation; blood quality testing products; blood freezers; blood banking, including pathogen inactivation; blood bag tube sealer; blood donor chairs; instrument for counting the number of leukocytes residual in blood; and device used to cut and connect both dry and wet blood bags.
In addition, the company sells mosquito trappers for outdoor and indoor use; and offers HPV and STI self-collect test kits under AVA name. The company was formerly known as Winnergy Medical Co., Ltd. and changed its name to Winnergy Medical Public Company Limited in September 2020.
Winnergy Medical Public Company Limited was incorporated in 2004 and is headquartered in Bangkok, Thailand.
Stock analysis
Winnergy Medical Public Company Limited (WINMED) currently trades at 1.18 THB, while our model-based Fair Value estimate is 0.5600 THB, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 1.06 THB per share, and 2 of the 12 models we run sit above the 1.18 THB price.
Bear case: the DCF Models group reads lowest at 0.0800 THB, and 10 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.2600 THB (bear) to 0.7100 THB (bull), the price of 1.18 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Winnergy Medical Public Company Limited reported revenue of 647M THB in FY2025 versus 539M THB in FY2021, a compound +4.7%/yr. Reported net income was 15.2M THB in FY2025, compounding −30.5%/yr from FY2021.
Key figures
Market cap 472M THB (≈ $14.1M) Micro · P/E ratio 29.5 · P/S ratio 0.68 · EPS (TTM) 0.0400 THB · Dividend yield 1.1% · Net margin 2.4% · Return on equity 2.6% · Return on assets (EBIT) 4.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −53%, WINMED screens richer than that median.
Fair Value models
Bear0.2600 THBFair Value 0.5600 THBBull0.7100 THB
Price 1.18 THB · Downside -52.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0232 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−20.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.7%
Dividend (yield on the price)1.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 1%
Compare Winnergy Medical Public Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−52.5% · Bottom 25%
Profitability
Return on equity (12 months)2.6% · Below median
Return on assets1.3% · Below median
Net margin (12 months)2.4% · Above median
Operating margin (12 months)7.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)38.8% · Top 25%
Dividend yield (12 months)1.1% · Bottom 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (12 months)29.5× · Priciest 25%
P/B0.74× · Cheaper than median
P/S (12 months)0.68× · Pricier than median
EV/EBITDA10.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 38
FUTURE (revenue growth)100· sector 24
PAST (return on equity)11· sector 28
HEALTH (low debt)92· sector 97
DIVIDEND (yield)22· sector 54
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Winnergy Medical Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/WINMED
Frequently asked questions
Is Winnergy Medical Public Company Limited (WINMED) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 0.5600 THB versus a price of 1.18 THB, about 53% lower (overvalued).
What is the fair value of WINMED?
Our model-based fair value for Winnergy Medical Public Company Limited is 0.5600 THB (as of Nov 5, 2026), built from audited fundamentals. The current price: 1.18 THB.
What is the quality score of WINMED?
Winnergy Medical Public Company Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Winnergy Medical Public Company Limited (WINMED)?
Our model-based price target is the fair value of 0.5600 THB (as of Nov 5, 2026) from 12 valuation models. Cautious scenario 0.2600 THB, optimistic scenario 0.7100 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Winnergy Medical Public Company Limited stock forecast for 2026?
Our models put fair value at 0.5600 THB, about 53% lower versus a price of 1.18 THB (overvalued). Cautious scenario 0.2600 THB, optimistic scenario 0.7100 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Winnergy Medical Public Company Limited (WINMED)?
Winnergy Medical Public Company Limited reported trailing-twelve-month revenue of about 700M THB (latest available figure, as of Nov 5, 2026).
Does Winnergy Medical Public Company Limited pay a dividend?
Winnergy Medical Public Company Limited currently shows a dividend yield of 1.10% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Winnergy Medical Public Company Limited (WINMED) and when is the ex-dividend date?
Winnergy Medical Public Company Limited pays a dividend of 0.013 THB per share a year, a dividend yield of 1.1%. The last ex-dividend date was Mar 16, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 32.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Winnergy Medical Public Company Limited (WINMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Winnergy Medical Public Company Limited it is 0.5600 THB per share (as of Nov 5, 2026), against a price of 1.18 THB. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Winnergy Medical Public Company Limited stock overvalued or undervalued in 2026?
As of Nov 5, 2026, WINMED trades above its calculated fair value: price 1.18 THB, fair value 0.5600 THB, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WINMED?
No. The price is what the market pays today (1.18 THB); the fair value is what the company's own numbers justify (0.5600 THB). For Winnergy Medical Public Company Limited the two are 0.6200 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Winnergy Medical Public Company Limited worth?
The market values Winnergy Medical Public Company Limited at about 472M THB (market capitalisation, as of Nov 5, 2026). Per share that is 1.18 THB; our models calculate a fair value of 0.5600 THB per share.
What do the bullish and bearish scenarios say about WINMED?
Our models span a range for Winnergy Medical Public Company Limited: cautious scenario 0.2600 THB, base 0.5600 THB, optimistic 0.7100 THB per share (as of Nov 5, 2026, price 1.18 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of WINMED?
Winnergy Medical Public Company Limited trades at a price-to-earnings ratio of 29.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.5600 THB is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 28.1. Other multiples: P/B 0.7, P/S 0.7, EV/EBITDA 10.9.
How solid is the balance sheet of Winnergy Medical Public Company Limited (WINMED)?
Balance-sheet figures for Winnergy Medical Public Company Limited (as of Nov 5, 2026): return on equity 2.6%, debt of 0.16 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is WINMED from its 52-week high?
Winnergy Medical Public Company Limited trades at 1.18 THB, about 13% below its 52-week high of 1.36 THB and 59% above the low of 0.7400 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.5600 THB is for.
Which stocks are comparable to Winnergy Medical Public Company Limited?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Winnergy Medical Public Company Limited stock attractive at the current price?
The data as of Nov 5, 2026: price 1.18 THB, calculated fair value 0.5600 THB (−53%), Quality Score 40/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WINMED calculated?
We run Winnergy Medical Public Company Limited through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.5600 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Winnergy Medical Public Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Winnergy Medical Public Company Limited (WINMED)?
The closing price on Nov 6, 2026 was 1.18 THB. Our model-based fair value is 0.5600 THB, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Winnergy Medical Public Company Limited right now?
The price sits above even our optimistic bull case (0.7100 THB). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (0.2600 THB to 0.7100 THB). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Winnergy Medical Public Company Limited
How large is the market capitalisation of Winnergy Medical Public Company Limited (WINMED)?
The market capitalisation of Winnergy Medical Public Company Limited is 472M THB (≈ $14.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Winnergy Medical Public Company Limited (WINMED)?
The price-to-sales ratio of Winnergy Medical Public Company Limited is 0.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Winnergy Medical Public Company Limited (WINMED)?
Earnings per share at Winnergy Medical Public Company Limited are 0.0400 THB (price ÷ EPS = P/E 29.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Winnergy Medical Public Company Limited (WINMED)?
The dividend yield of Winnergy Medical Public Company Limited is 1.1% (payout 32.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Winnergy Medical Public Company Limited (WINMED)?
The net margin of Winnergy Medical Public Company Limited is 2.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Winnergy Medical Public Company Limited (WINMED)?
The return on equity (ROE) of Winnergy Medical Public Company Limited is 2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Winnergy Medical Public Company Limited (WINMED)?
On an EBIT basis the return on assets of Winnergy Medical Public Company Limited is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Winnergy Medical Public Company Limited (WINMED)?
The operating margin of Winnergy Medical Public Company Limited is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Winnergy Medical Public Company Limited (WINMED)?
Revenue at Winnergy Medical Public Company Limited is growing +38.8% versus a year earlier (3y avg −2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Winnergy Medical Public Company Limited (WINMED)?
Earnings per share at Winnergy Medical Public Company Limited are growing +237% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Winnergy Medical Public Company Limited (WINMED) generate?
The free cash flow of Winnergy Medical Public Company Limited is −58.1M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Winnergy Medical Public Company Limited (WINMED) carry?
The net debt of Winnergy Medical Public Company Limited is 343M THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Winnergy Medical Public Company Limited in the live analysis
One click puts Winnergy Medical Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026